Literature DB >> 7945737

Placebo as a treatment for depression.

W A Brown1.   

Abstract

The placebo response rate in depression consistently falls between 30 and 40%. Among more severely depressed patients antidepressants offer a clear advantage over placebo; among less severely depressed patients and those with a relatively short episode duration the placebo response rate is close to 50% and often indistinguishable from the response rate to antidepressants. In the treatment of depression none of the psychotherapies have consistently been shown to offer an advantage over pill placebo. This is not entirely surprising given the fact that the common, and arguably the therapeutic, features of the psychotherapies (expectation of improvement, support, mobilization of hope) are provided with pill placebo treatment. The placebo response in depression has been viewed as a nuisance rather than as a therapeutic and research opportunity. I propose that the initial treatment for selected depressed patients should be four to six weeks of placebo. Patients so treated should be informed that the placebo pill contains no drug but that this treatment can be helpful.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945737     DOI: 10.1038/npp.1994.53

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  23 in total

Review 1.  Placebos in clinical practice and research.

Authors:  P P De Deyn; R D'Hooge
Journal:  J Med Ethics       Date:  1996-06       Impact factor: 2.903

2.  The use of placebos in psychiatry: a response to the draft document prepared by the Tri-Council Working Group. Canadian College of Neuropsychopharmacology.

Authors:  S N Young; L Annable
Journal:  J Psychiatry Neurosci       Date:  1996-07       Impact factor: 6.186

3.  Assessing placebo response using Bayesian hierarchical survival models.

Authors:  D K Stangl; J B Greenhouse
Journal:  Lifetime Data Anal       Date:  1998       Impact factor: 1.588

4.  The placebo effect and its clinical associations in gambling disorder.

Authors:  Jon E Grant; Samuel R Chamberlain
Journal:  Ann Clin Psychiatry       Date:  2017-08       Impact factor: 1.567

Review 5.  Role of placebo effects in pain and neuropsychiatric disorders.

Authors:  Annabelle M Belcher; Sergi Ferré; Pedro E Martinez; Luana Colloca
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-06-14       Impact factor: 5.067

Review 6.  Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis.

Authors:  Jennifer L Couturier
Journal:  J Psychiatry Neurosci       Date:  2005-03       Impact factor: 6.186

Review 7.  Placebo eff ects in psychiatry: mediators and moderators.

Authors:  Katja Weimer; Luana Colloca; Paul Enck
Journal:  Lancet Psychiatry       Date:  2015-03       Impact factor: 27.083

8.  A comparison of placebo responders and nonresponders in subgroups of depressive disorder.

Authors:  R J Bialik; A V Ravindran; D Bakish; Y D Lapierre
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

9.  Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.

Authors:  Roger D Weiss; Stephanie S O'malley; James D Hosking; Joseph S Locastro; Robert Swift
Journal:  J Stud Alcohol Drugs       Date:  2008-11       Impact factor: 2.582

10.  The development and psychometric evaluation of the Motivation and Energy Inventory (MEI).

Authors:  S E Fehnel; C M Bann; S L Hogue; W J Kwong; S S Mahajan
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.